Major research project opportunities for cancer researchers working in on RET-positive specific TKIs, immunotherapies and related fields
It is a priority for RET Positive to fund proposals that seek to overcome or prevent the mechanisms of resistance that develop with RET targeted therapies, to better understand why up to 25% of patients fail to respond to the current RET targeting agents or why not every patient becomes NED, why RET targeting projects seem to fail to respond to immunotherapies or to identify T cell receptors that might react to RET driven cancers, and finally to fund projects looking at novel approaches to overcoming malignancies driven by RET fusions or mutations, including those involving CRISPR or protein degraders. By funding projects that seek to overcome or prevent resistance to established RET medications, or by helping advance research in RET-specific immunotherapies or related fields, we hope to transform RET-positive cancer into a manageable chronic condition.
If you are a researcher or other potential partner, please contact us here.
RET cancer patients are relatively few and far between, and we understand it can be challenging to stay up-to-date on every new development relevant to their treatment. This is why one of our goals is to provide short format, high-quality summaries of the latest advances in the management of RET-driven cancers based on peer-reviewed publications and evidence based data. We forward the latest reports from conferences such as AACR, ASCO, ESMO and more in our mailing list specifically aimed at providing Clinicians with latest updates relevant to the treatment of patients with RET driven Cancers.